You are here

Ready-to-Use Rescue Pen Successfully Treats Hypoglycemia in Diabetes Patients

Company to discuss mid-stage data with FDA

Encouraging results have been reported from a phase 2 trial of a single-dose version of dasiglucagon (Zealand Pharma) as rescue treatment for severe hypoglycemia in insulin-dependent patients with type-1 diabetes. Dasiglucagon, formerly known as ZP4207, is a glucagon peptide analogue with physical and chemical stability in liquid solution.

Severe hypoglycemia is a potentially life-threatening condition associated with insulin treatment of diabetes. Current hypoglycemia rescue treatments are based on native glucagon and are available only as a lyophilized powder, which requires reconstitution with sterile water before use.

The primary objective of the new study was to characterize the pharmacological profile of an optimized formulation of single-dose dasiglucagon and to compare it with an approved glucagon rescue product in 81 individuals with type-1 diabetes. Results from the study showed that all patients treated with one of the three highest doses of dasiglucagon or with the approved glucagon product achieved a blood glucose concentration of greater than 70 mg/dL within 30 minutes of dosing. In the same dose groups, the time to clinically relevant plasma glucose increases of greater than 20 mg/dL was shown to be similar for dasiglucagon and approved glucagon, with a median time of nine to 10 minutes. Dasiglucagon was well tolerated and had a safety profile similar to that of approved glucagon.

Armed with these new data, Zealand Pharma plans to talk to the FDA about moving dasiglucagon into phase 3 trials.

The major appeal of single-dose dasiglucagon lies in its shelf life, according to FierceBiotech. By creating a glucagon peptide analogue stable enough to be kept in a liquid solution, Zealand Pharma hopes to provide diabetic patients with a rescue pen that is ready to use. Single-dose dasiglucagon is also central to an artificial pancreas that Zealand is developing with Beta Bionics.

Sources: Zealand Pharma; August 11, 2016; and FierceBiotech; August 12, 2016.

More Headlines

Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Policy Could Be Life-Changing for People With Spinal Cord Injury
Test Determines Severity of Pain, Helps Physicians Select Best Options
Intratumoral Injection Stimulates Immune Activation
Diabetes and Cancer Patients Could Soon Avoid Injections
Early Cancer Development May Begin in Just 30 Minutes